This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Exelixis (EXEL) reported $628.69 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 10.6%. EPS of $0.91 for the same period compares to $0.75 a year ago.

The reported revenue represents a surprise of -0.99% over the Zacks Consensus Estimate of $635 million. With the consensus EPS estimate being $0.86, the EPS surprise was +5.81%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Exelixis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Net product revenues: $573.03 million versus the six-analyst average estimate of $582.81 million. The reported number represents a year-over-year change of +10.2%.
Revenues- Collaboration revenues: $55.67 million versus $52.17 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +15.4% change.
Revenues- Net product revenues- CABOMETYX: $570.6 million versus the five-analyst average estimate of $578.01 million. The reported number represents a year-over-year change of +10.2%.
Revenues- Net product revenues- COMETRIQ: $2.4 million versus $2.75 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +13% change.
Revenues- Collaboration revenues- Collaboration services revenues: $-4.15 million compared to the $2.24 million average estimate based on two analysts. The reported number represents a change of +293.3% year over year.
Revenues- Collaboration revenues- License revenues: $59.81 million compared to the $52.31 million average estimate based on two analysts. The reported number represents a change of +21.3% year over year.

View all Key Company Metrics for Exelixis here>>>

Shares of Exelixis have returned -1.9% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research